MetaCap

Taysha Gene Therapies Inc. (TSHA)

NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

3.72-0.05 (-1.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TSHA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.42
52-week range
3.46 – 7.30
Day range
3.60 – 3.80
Volume / Avg
3.15M / 3.59M
Beta
—

52-week range

$3.46$7.30

TSHA stock today

Taysha Gene Therapies (TSHA) closed at $3.72 on Nov 20, down 1.33% (-$0.05), versus the S&P 500's 3.70% decline. At this level, TSHA sits near the bottom of its 52-week range of $3.46 to $7.30: 49.0% below the high, set on May 6, 2026 and 7.7% above the low. TSHA is down 32.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 11.2%.

Taysha Gene Therapies has posted a net loss over the last twelve months (EPS of -$0.42), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Taysha Gene Therapies

Company profile

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Sean P. Nolan
Headquarters
Dallas, TX
Employees
99
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Taysha Gene Therapies generated $9.8 million in revenue, up 17.3% from fiscal 2024. Taysha Gene Therapies reported a net loss of $109.0 million, compared with a loss of $89.3 million a year earlier. Operating margin was -1130.6%.

Taysha Gene Therapies annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$9.77M$8.33M$15.45M$2.50M—
Growth+17.28%-46.07%+517.55%——
Net income$-109.00M$-89.30M$-111.57M$-166.01M$-174.52M
EPS (diluted)$-0.34$-0.36$-0.96$-3.78$-4.64

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$13.00+249.46%

  • Strong buy 3
  • Buy 10
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $19.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.10 vs $-0.14
Surprise
+28.57%

TSHA news

All TSHA news

Taysha Gene Therapies peers

Health Care sector
TSHA peer companies
CompanyPrice% ChgMarket capCompare
NVAXNovavax Inc.7.47-3.24%$1.23Bvs TSHA
VORVor Biopharma Inc.19.19+3.62%$1.18Bvs TSHA
IMCRImmunocore Holdings plc ADR26.41-0.83%$1.36Bvs TSHA
MESOMesoblast Limited ADR10.89-2.59%$1.41Bvs TSHA
INBXInhibrx Biosciences Inc.68.97-7.21%$1.02Bvs TSHA
WWBWindward Bio Group AG24.29+1.15%$1.45Bvs TSHA
ALVOAlvotech4.12-3.96%$1.47Bvs TSHA
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs TSHA

Indexes, lists and sector

Taysha Gene Therapies stock FAQ

What is Taysha Gene Therapies's stock price today?

TSHA last traded at $3.72 as of Nov 20, 4:00 PM EST, down 1.33% on the day. Prices are delayed at least 15 minutes.

Who is Taysha Gene Therapies's CEO?

Mr. Sean P. Nolan is the chief executive officer of Taysha Gene Therapies Inc., which has about 99 employees.

What is the TSHA 52-week high?

The 52-week high for TSHA is $7.30 and the 52-week low is $3.46. The stock is currently 49.0% below its high.

Compare TSHA